An unforeseen reality : hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis

Blagotinšek Ošep, Anka (avtor), Brecl, Eva (avtor), Škerget, Matevž (avtor), Savšek, Lina (avtor)

Alemtuzumab is a humanized monoclonal antibody indicated for treatment of highly active relapsing-remitting multiple sclerosis (HA-RRMS). It binds to CD52 antigen and produces a rapid and prolonged lymphocyte depletion followed by a different pattern of T and B cell repopulation. Among others, its adverse events are autoimmune diseases. In this article, we present a patient with HA-RRMS, who was subsequently treated with alemtuzumab and afterwards developed hemophagocytic lymphohistiocytosis (HLH). Albeit rarely, HLH can be triggered by alemtuzumab treatment. HLH can favourably respond to prompt immunosuppressant therapy. Multidisciplinary approach by a team consisting of a neurology, hematology and rheumatology specialist is needed to treat this potentially lethal condition.

• Jezik: Angleški jezik
• Ključne besede: multiple sclerosis, alemtuzumab, hemophagocytic lymphohistiocytosis, side effects, neuroimmunology, drug therapy, adverse effects
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.03 - Kratki znanstveni prispevek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2023
• Št. strani: 3 str.
• Številčenje: Vol. 228, art. 107675
• PID: 20.500.12556/RUL-148285
• UDK: 616.8
• ISSN pri članku: 1872-6968
• DOI: 10.1016/j.clineuro.2023.107675
• COBISS.SI-ID: 154225155
• Datum objave v RUL: 09.08.2023

Gradivo je del revije

• Naslov: Clinical neurology and neurosurgery
• Založnik: Elsevier
• ISSN: 1872-6968
• COBISS.SI-ID: 518749209

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: multipla skleroza, terapija z zdravili, alemtuzumab, škodljivi učinki, hemofagocitna limfohistiocitoza